Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Gene therapy of rare diseases as a milestone in medicine : overview of the field and report on initial experiences in Slovenia
Authors:ID Grošelj, Urh (Author)
ID Kavčič, Marko (Author)
ID Drole Torkar, Ana (Author)
ID Kafol, Jan (Author)
ID Lainšček, Duško (Author)
ID Jerala, Roman (Author)
ID Sever, Matjaž (Author)
ID Zver, Samo (Author)
ID Serša, Gregor (Author)
ID Čemažar, Maja (Author)
ID Strojan, Primož (Author)
ID Grošelj, Aleš (Author)
ID Žerjav-Tanšek, Mojca (Author)
ID Miroševič, Špela (Author)
ID Ivančan, Simona (Author)
ID Prelog, Tomaž (Author)
ID Gosar, David (Author)
ID Oražem, Jasna (Author)
ID Mlinarič, Matej (Author)
ID Bertok, Sara (Author)
ID Kovač, Jernej (Author)
ID Kodrič, Jana (Author)
ID Battelino, Saba (Author)
ID Pokorn, Marko (Author)
ID Ihan, Alojz (Author)
ID Jazbec, Janez (Author)
ID Battelino, Tadej (Author)
ID Osredkar, Damjan (Author)
Files:.pdf PDF - Presentation file, download (2,18 MB)
MD5: 21E3F217C61C507609D10517BFDF3594
 
URL URL - Source URL, visit https://link.springer.com/article/10.1186/s13023-025-03828-8
 
Language:English
Typology:1.02 - Review Article
Organization:Logo UKC LJ - Ljubljana University Medical Centre
Abstract:Gene therapy has transitioned from a long-awaited promise to a clinical reality, offering transformative treatments for rare congenital diseases and certain cancers, which have a significant impact on patients’ lives. Current approaches focus on gene replacement therapy, either in vivo or ex vivo, mostly utilizing viral vectors to deliver therapeutic genes into target cells. However, refining these techniques is essential to overcome challenges and complications associated with gene therapy to ensure long-term safety and efficacy. Slovenia has witnessed significant advancements in this field since 2018, marked by successful gene therapy trials and treatments for various rare diseases. Significant strides have been made in the field of gene therapy in Slovenia, treating patients with spinal muscular atrophy and rare metabolic disorders, including the pioneering work on CTNNB1 syndrome. Additionally, immune gene therapy, exemplified by IL-12 adjuvant therapy for cancer, has been a focus of research in Slovenia. Through patient-centred initiatives and international collaborations, researchers in Slovenia are advancing preclinical research and clinical trials, paving the way for accessible gene therapies. Establishing clinical infrastructure and genomic diagnostics for rare diseases is crucial for gene therapy implementation. Efforts in this regard in Slovenia, including the establishment of a Centre for Rare Diseases, Centre for the Technologies of Gene and Cell Therapy, and rapid genomic diagnostics, demonstrate a commitment to comprehensive patient care. Despite the promises of gene therapy, challenges remain, including cost, distribution, efficacy, and long-term safety. Collaborative efforts are essential to address these challenges and ensure equitable access to innovative therapies for patients with rare diseases.
Keywords:gene therapy, rare genetic diseases, Slovenia, CAR-T cells, cancer, immune gene therapy
Publication status:Published
Publication version:Version of Record
Year of publishing:2025
Number of pages:str. 1-10
Numbering:Vol. 20, article no. 279
PID:20.500.12556/DiRROS-24530 New window
UDC:606:616-056.7
ISSN on article:1750-1172
DOI:10.1186/s13023-025-03828-8 New window
COBISS.SI-ID:238642179 New window
Note:Nasl. z nasl. zaslona; Opis vira z dne 8. 6. 2025;
Publication date in DiRROS:04.12.2025
Views:29
Downloads:12
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Orphanet journal of rare diseases
Publisher:BioMed Central
ISSN:1750-1172
COBISS.SI-ID:514009369 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0343-2022
Name:Etiologija, zgodnje odkrivanje in zdravljenje bolezni pri otrocih in mladostnikih

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J7-4640-2022
Name:Inovativna imunoterapija raka preko CAR T celic (CARRS)

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J7-4537-2022
Name:POVEZAVA MED GENOTIPOM IN FENOTIPOM PRI SINDROMU CTNNB1 IN NOVI PRISTOPI K ZDRAVLJENJU TEGA SINDROMA

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-4526-2022
Name:Himerna avtologna vakcina proti PCSK9

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J4-4563-2022
Name:Uporaba izboljšanega sistema CRISPR/Cas za nevirusno produkcijo celic CAR-T

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L3-50111-2023
Name:Genska imunska terapija čvrstih tumorjev na osnovi mRNA z zapisom za interlevkin-12: So-rIL

Funder:EC - European Commission
Project number:101059842
Name:Centre of Excellence for the Technologies of Gene and Cell Therapy
Acronym:CTGCT

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Back